News | May 11, 2022
Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
The company dispatched the first batch of essential medicines worth US $ 30,000 to Ukraine through its embassy in New Delhi
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
Subscribe To Our Newsletter & Stay Updated
